Table 3. Patient Characteristics by Monosomal Karyotype and IPSS at Diagnosis.
| IPSS | R-IPSS | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Variable | No MK | MK | P- value |
Good | Intermediate | Poor | P- value |
Good/ Very Good |
Intermediate | Poor | Very Poor | P- value |
|
| Age of Patient | < 50 | 26 (31%) | 13 (36%) | 0.82 | 6 (17%) | 14 (50%) | 20 (35%) | 0.03 | 6 (17%) | 11 (46%) | 15 (47%) | 8 (28%) | 0.04 |
| 50-60 | 32 (39%) | 14 (39%) | 13 (37%) | 8 (29%) | 25 (43%) | 13 (36%) | 8 (33%) | 11 (34%) | 14 (48%) | ||||
| >60 | 25 (30%) | 9 (25%) | 16 (46%) | 6 (21%) | 13 (22%) | 17 (47%) | 5 (21%) | 6 (19%) | 7 (24%) | ||||
| Age (Years) | Median (range) | 55 (19-72) | 52 (19-69) | 0.88 | 58 (27-72) | 52 (21-69) | 52 (19-72) | 0.11 | 59 (27-72) | 53 (28-69) | 51 (19-72) | 53 (22-69) | 0.17 |
| Patient Gender | Male | 55 (66%) | 24 (67%) | 0.97 | 23 (66%) | 17 (61%) | 40 (69%) | 0.75 | 23 (64%) | 16 (67%) | 23 (72%) | 18 (62%) | 0.86 |
| KPS | <90 | 19 (23%) | 5 (14%) | 0.29 | 6 (17%) | 7 (25%) | 11 (19%) | 0.73 | 7 (19%) | 6 (25%) | 7 (22%) | 4 (14%) | 0.80 |
| 90/100 | 64 (77%) | 30 (83%) | 29 (83%) | 21 (75%) | 46 (79%) | 29 (81%) | 18 (75%) | 25 (78%) | 24 (86%) | ||||
| Recipient CMV | Positive | 46 (55%) | 19 (53%) | 19 (54%) | 18 (64%) | 28 (48%) | 0.38 | 20 (56%) | 16 (67%) | 14 (44%) | 15 (52%) | 0.39 | |
| Donor Type | RD/URD Match | 42 (51%) | 23 (64%) | 0.44 | 17 (49%) | 14 (50%) | 35 (60%) | 0.19 | 18 (50%) | 12 (50%) | 16 (50%) | 20 (69%) | 0.22 |
| RD/URD MM | 6 (7%) | 2 (6%) | 2 (6%) | 4 (14%) | 2 (3%) | 2 (6%) | 4 (17%) | 1 (3%) | 1 (3%) | ||||
| UCB 5+6/6 | 19 (23%) | 4 (11%) | 11 (31%) | 3 (11%) | 10 (17%) | 11 (31%) | 3 (13%) | 6 (19%) | 4 (14%) | ||||
| UCB 4/6 | 16 (19%) | 7 (19%) | 5 (14%) | 7 (25%) | 11 (19%) | 5 (14%) | 5 (21%) | 9 (28%) | 4 (14%) | ||||
| Conditioning | MA | 32 (39%) | 13 (36%) | 0.97 | 11 (31%) | 11 (39%) | 24 (41%) | 0.78 | 11 (31%) | 8 (33%) | 16 (50%) | 11 (38%) | 0.61 |
| RIC: w/ ATG | 35 (42%) | 16 (44%) | 17 (49%) | 10 (36%) | 24 (41%) | 18 (50%) | 9 (38%) | 11 (34%) | 13 (45%) | ||||
| RIC: w/o ATG | 16 (19%) | 7 (19%) | 7 (20%) | 7 (25%) | 10 (17%) | 7 (19%) | 7 (29%) | 5 (16%) | 5 (17%) | ||||
| GvHD Prophylaxis | CSA/MMF | 52 (63%) | 21 (58%) | 0.57 | 23 (66%) | 18 (64%) | 32 (55%) | 0.77 | 24 (67%) | 17 (71%) | 17 (53%) | 15 (52%) | 0.49 |
| CSA containing | 21 (25%) | 8 (22%) | 8 (23%) | 7 (25%) | 15 (26%) | 8 (22%) | 4 (17%) | 11 (34%) | 7 (24%) | ||||
| Other | 10 (12%) | 7 (19%) | 4 (11%) | 3 (11%) | 11 (19%) | 4 (11%) | 3 (13%) | 4 (13%) | 7 (24%) | ||||
| Diagnosis | MDS-NOS | 12 (15%) | 10 (28%) | 0.30 | 6 (17%) | 5 (18%) | 13 (22%) | 0.04 | 6 (17%) | 5 (21%) | 13 (21%) | 5 (17%) | 0.05 |
| MDS - RA | 5 (6%) | 0 | 1 (3%) | 2 (7%) | 2 (3%) | 1 (3%) | 3 (13%) | 1 (3%) | 0 | ||||
| MDS - RAEB-1 | 21 (25%) | 11 (31%) | 7 (20%) | 6 (21%) | 19 (33%) | 18 (50%) | 4 (17%) | 2 (6%) | 6 (21%) | ||||
| MDS - RAEB-2 | 25 (30%) | 5 (14%) | 18 (51%) | 5 (18%) | 7 (12%) | 2 (6%) | 0 | 1 (3%) | 1(3%) | ||||
| MDS - RARS | 3 (4%) | 1 (3%) | 1 (3%) | 1 (4%) | 2 (3%) | 1 (3%) | 5 (21%) | 7 (22%) | 8 (28%) | ||||
| MDS - RCMD | 13 (16%) | 8 (22%) | 1 (3%) | 7 (25%) | 13 (22%) | 1 (3%) | 2 (8%) | 1 (3%) | 1 (3%) | ||||
| RCMD - RS | 4 (5%) | 1 (3%) | 1 (3%) | 2 (7%) | 2 (3%) | 7 (19%) | 5 (21%) | 12 (38%) | 8 (28%) | ||||
| Therapy-related MDS | yes | 13 (16%) | 13 (36%) | 0.01 | 16 (46%) | 5 (18%) | 6 (10%) | <0.01 | 1 (3%) | 4 (17%) | 13 (41%) | 19 (68%) | <0.01 |
| Blast at TX | <=2% | 46 (55%) | 27 (75%) | 0.07 | 21 (60%) | 15 (54%) | 38 (66%) | 0.53 | 22 (61%) | 13 (54%) | 18 (56%) | 21 (72%) | 0.61 |
| >2-<5% | 25 (30%) | 4 (11%) | 11 (31%) | 8 (29%) | 11 (19%) | 11 (31%) | 7 (29%) | 8 (25%) | 4 (14%) | ||||
| 5-10% | 12 (15%) | 5 (14%) | 3 (9%) | 5 (18%) | 9 (16%) | 3 (8%) | 4 (17%) | 6 (19%) | 4 (14%) | ||||
| Chemotherapy | No | 43 (52%) | 16 (44%) | 0.46 | 34 (97%) | 23 (85%) | 35 (61%) | <0.01 | 35 (97%) | 23 (96%) | 24 (80%) | 1 (3%) | <0.01 |
| Yes | 40 (48%) | 20 (56%) | 1 (3%) | 4 (15%) | 22 (39%) | 1 (3%) | 1 (4%) | 6 (20%) | 28 (97%) | ||||
| MK | No | 34 (97%) | 27 (96%) | 22 (39%) | <0.01 | 6.7 (1-372) | 7.4 (2-63) | 5.4 (2-73) | 5.2 (2-38) | 0.06 | |||
| Yes | 1 (3%) | 1 (4%) | 34 (61%) | 1 (3%) | 4 (17%) | 13 (41%) | 19 (68%) | <0.01 | |||||
| Months to AlloHCT | Median (range) | 6.7 (1-372) | 5.3 (2-39) | 0.14 | 6.3 (1-77) | 10.4 (2-81) | 5.3 (2-372) | 0.58 | 22 (61%) | 13 (54%) | 18 (56%) | 21 (72%) | 0.61 |